THE LATEST DEVELOPMENTS IN SYSTEMIC TREATMENT FOR HEPATOCELLULAR CARCINOMA.

Hepatocellular carcinoma (HCC) stands as one of the most prevalent and deadly malignant tumors globally. Treatment options for advanced HCC are currently limited, with systemic approaches, particularly involving conventional cytotoxic drugs, often proving ineffective. For more than a decade, sorafenib has stood as the sole clinically proven systemic drug for treating advanced HCC. Nevertheless, the treatment landscape for advanced HCC has undergone significant transformation in the past three years, owing to the rapid advancements in molecular targeted therapies. The integration of immune checkpoint therapies into HCC treatment protocols is now underway, and their combination with molecular targeted therapy is emerging as a promising strategy to bolster the immune response. This review provides a comprehensive summary of the development and progress of molecular targeted agents and immunotherapies in the context of HCC.